Hakimeh Zali et al., J Women's Health Care 2018, Volume 7
DOI: 10.4172/2167-0420-C2-011

conferenceseries.com

10th World Congress On

Precision & Personalized Medicine

October 05-06, 2018 Osaka, Japan

Genetic variation associated Cetuximab resistance in Iranian colorectal cancer

Hakimeh Zali, Padina Vaseghi Maghvan Alireza Rezvani, Mohammad Esmaiil Akbari, Mostafa Rezaei-Tavirani, Nafiseh Ansarinejad, Maryam Nouri and Leyla Asef Kabiri

Shahid Beheshti University of Medical Sciences and Health Services, Iran

Colorectal Cancer (CRC) is a heterogeneous disease which leads to clinical and pathological diversity in tumors that result in genetic and biological heterogeneity. These diversity leads to see divergence in response and drug resistance. Even in those tumors with similar histopathological features could be seen different responses. Genetic basis and genetic interaction with environment which is related to patients' life style leads into variable specific molecular features for colorectal cancer. Classifying the patients into separate groups which could suggest the best therapeutic approach in the field of personalized medicine in where dividing the patients based on genetic and epigenetic factors susceptible for specific disease. In this study, we are going to determined genetic factors that cause heterogeneity in colorectal cancer Iranian patients in metastatic stage with different responses to EGFR inhibitors. We have been evaluated 70 patients in metastatic stages who were candidate for EGFR inhibitors in threes big city during 3 years. Patients selected based on molecular and pathological characteristics with N-Ras, K-Ras and BRAF wild-type genes, then all candidate patients have been administrated cetuximab. At least one year followed up illustrated more than 70% of patients with non-responding. We collected the paraffin pathological blocks to find the genes related drug resistance in Iranian population suffers from CRC. This ongoing study will reveal the genetic signs of CRC in Iranian population and also determine the personalized administration EGFR inhibitors.

Biography

Hakimeh Zali has completed her PhD in Applied Proteomics from Shahid Beheshti University. She is currently working as an Assistant Professor in the School of Advanced Technology in Medicine, Shahid Beheshti University of Medical Sciences. She has published more than 55 papers in reputed journals.

hakimehzali@gmail.com

Notes: